TRUSTSWAP
24.8.2021 22:41:13 CEST | Business Wire | Press release
Jani Leinonen, the renowned Finnish artist, will offer a 3 day NFT auction of his one-of-one animated artwork titled ‘Things You Own’, on Swappable , until Friday, August 27th at 10am PST. Swappable is a new interface for non-fungible tokens (NFTs) powered by TrustSwap .
Leinonen will be participating in an AMA Ask-Me-Anything event, offering the opportunity for the community to ask him questions.
Leinonen’s first NFT is supported by Stalla Madulain , the renowned Swiss art gallery dating back to 1488 and one of his most ardent supporters. As well as Switzerland-based international fine art logistics and infrastructure provider Haas & Company AG , a reputed partner of art collectors, galleries, museums, and art fairs worldwide which provides custody services for tokenized physical assets.
Swappable, powered by TrustSwap , will create a creative place for artists to sell their artworks and for users to find and collect artworks and digital collectibles. Jeff Kirdeikis, CEO of TrustSwap, mentions: “We are extremely excited to be working with such a renowned artist, we’ve created a platform that reduces the entrance barrier to the NFT space to support creators like Jani Leinonen.”
Leinonen is known for his provocative, yet playful works, criticizing capitalism and consumerism. In 2016, Leinonen was awarded the Finland Prize by the Ministry of Education and Culture, which is given in recognition of a significant career in arts. His work can be found in museums, and in private and public collections on every continent. He is currently exhibiting in Serlachius Museum with the street artist Banksy, and Salo Art Museum. The Five-star hotel Dolder Grand in Zurich has 12 of Leinonen’s works on permanent display. You can find out more about Leinonen on his website .
Jani Leinonen, on his NFT artwork ‘Things you own’: “Have we become more consumers than citizens? Our values, our political views, our emotions, traumas, and our dreams, are revealed by this sacred shopping cart. When we take a look at this portrait of us, how much do we recognize as our own? Will there truly be a new better world displacing the established and old, or will we forever be owned by the things we own?”
The team behind Swappable boasts that the Jani Leinonen collaboration is just the beginning, with many interesting collaborations to be revealed soon.
Swappable is the latest offering from TrustSwap
TrustSwap is a blockchain venture that offers smart contact services and innovative solutions for decentralized finance (DeFi) and commerce to help the crypto community transact with integrity, and accountability. TrustSwap solves problems in the DeFi space connected to tracking and buying crypto with ‘The Crypto App’, split payments, subscriptions, escrow, minting, token locks, and fundraising. TrustSwap is building foundational layers in the rapidly-emerging decentralized finance and commerce landscape with services like The Crypto App, SmartLocks, Mint, Launchpad, and Swappable’s NFT interface. Visit www.trustswap.org for information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210824005826/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom